Anti-oncogenic drugs - In order to grow, tumor cells produce chemical growth factors by switching on oncogenes. Many tumors rely on a mutation of the RAS oncogene in order to develop. Scientists ...

Problems arise, however, when mutations convert the proto-oncogene to an oncogene, rendering Ras permanently active regardless of the signals the cell receives. How do tumor suppressors differ?

The new study in animal models will investigate whether “initiated” cells, harboring a mutant RAS oncogene, can be eliminated with LB-100. If successful, LB-100 could have a significant role in the ...

But as you know, Amgen and Mirati are not the only ones in hot pursuit. At the 1 st RAS- Targeted Drug Discovery Summit Europe, 23 other leading organisations will demonstrate how they are ...

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

Servier will be responsible for development and global commercialisation of the therapy for several indications.

Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC). This is an ASCO Meeting ...